Use of melanocortin-4 receptor agonists to treat lepr and / or sh2b1 deficiency

CL202602202A1Pending Publication Date: 2026-08-21RHYTHM PHARMACEUTICALS INC +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202602202
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-12-26
Filing Date: 2026-06-25
Publication Date: 2026-08-21

Application Information

Patent Timeline

26 Dec 2024

Priority

25 Jun 2026

Application

CL202602202

21 Aug 2026

Publication

CL202602202A1

IPC: A61K31/5377; A61K31/33; A61K31/395; A61K31/535; C07D207/02

CPC: C07D207/16; A61K31/5377

Inventors: PARK Hee Dong; HWANG Hye Kyeong

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The invention relates to the use of a compound of chemical formula I or a pharmaceutically acceptable salt thereof for preventing, improving, or treating a genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particularly a genetic obesity disease associated with SH2B1 deficiency or LEPR deficiency.

Need to check novelty before this filing date? Find Prior Art